Summary
Signal counts
Assets tracked: 3
Watchlist assets: 3
Registry stop assets: 3
Sponsor overview
Genentech, .
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT02569801 | https://clinicaltrials.gov/study/NCT01823835 | https://clinicaltrials.gov/study/NCT00063154 | https://clinicaltrials.gov/study/NCT02411344 | https://clinicaltrials.gov/study/NCT02480010
Assets
Linked programs
- Fulvestrant: Registry Stop Signal (4/5)
- GDC-0810: Registry Stop Signal (4/5)
- Pertuzumab: Registry Stop Signal (5/5)